In addition, several other ECM components, such as fibronectin, hyaluronan, TGF-β, integrins involved in mechanotransduction, and other sensors of matrix stiffness, are being studied as potential therapeutic targets in various cancers, including CRC [218]. The gene discussed is TGFB1; the disease is colorectal carcinoma.